Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to Assess Antigen-Specific Immune Responses Group A Strep Is Responsible for Approximately 800 Million New Cases of Illness and More Than 600,000 Deaths Annually Worldwide, with No Approved Vaccine and Sign